FAST NEWS: Henlius expects first-ever annual profit on strong drug sales
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Monday it expects to report a net profit of 500 million yuan ($69.5 million) or more for 2023, reversing a loss of 695 million…
Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part
Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key…
RELATED ARTICLES
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK -
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
- CHINA BULLETIN: Manufacturing Déjà Vu
- CHINA BULLETIN: Factories Send Mixed Signals
- CHINA BULLETIN: Services, Trade Send Positive Signals
